## Alkem Laboratories Limited (ALKEM) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Alkem Laboratories Limited (ALKEM) is a pharmaceutical company listed on the National Stock Exchange of India (NSE) on December 23, 2015.  It operates within the Pharmaceuticals & Biotechnology sector, specifically focusing on pharmaceuticals.  The company's exact positioning within the sector requires further research beyond the provided data, but its presence on the NSE indicates a significant market share and established presence.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹5,425.00       | Closed at ₹5,427.50; slight dip from the close.                     |
| Percentage Change (PChange) | -1.26%          | Negative daily change.                                                |
| Pre-Open Activity          | ₹5,535.00       | Opened higher than the previous close, indicating initial buying pressure.|
| Week High                    | ₹6,439.90       | Significant high within the week, suggesting recent volatility.       |
| Week Low                     | ₹4,407.05       | Significant low within the week, further highlighting volatility.     |
| VWAP                        | ₹5,468.69       | Volume Weighted Average Price; slightly higher than the closing price.|
| Sector PE                   | 29.68           | Sector Price-to-Earnings ratio.                                      |
| Symbol PE                   | 30.4            | Company's Price-to-Earnings ratio; slightly higher than the sector average.|
| Delivery Percentage         | 50.38%          | Moderate delivery percentage; suggests a mix of long-term and short-term investors.|
| Market Depth                | Low              | Based on the provided order book data (total buy/sell quantity = 0), market depth appears low, indicating potential for price swings.  Further investigation is needed. |


**3. Financial Performance:**

The provided financial data shows a mixed performance over the past five quarters.  While revenue and profit after tax have generally increased, there's significant quarter-to-quarter fluctuation.  The impact of exceptional items (cybersecurity incident and impairment loss) needs careful consideration.

| Quarter      | Revenue (₹) | Expenses (₹) | Profit After Tax (₹) | Diluted EPS (₹) |
|--------------|-------------|-------------|----------------------|-----------------|
| Q1 2024      | 244,916     | 204,763     | 32,497.07            | 27.18            |
| Q2 2024      | 260,620     | 196,526     | 58,325              | 48.78            |
| Q3 2024      | 299,216     | 222,449     | 69,758              | 58.34            |
| Q4 2023      | 259,025     | 200,456     | 50,423              | 42.17            |
| Q3 2023      | 269,643     | 205,771     | 64,651              | 54.07            |


**Key Financial Ratios:**  Further analysis is needed to calculate key ratios (e.g., Return on Equity, Debt-to-Equity) using complete financial statements.  The provided data only offers a partial picture.

**4. Corporate Actions and Announcements:**

Alkem Laboratories has a history of consistent dividend payouts, both interim and final.  Recent announcements include board meetings to discuss financial results and a newspaper publication.  The acquisition announcement requires further investigation to assess its impact.  The cybersecurity incident and plant divestment are significant events that need to be factored into the analysis.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|--------------------|-----------|
| 30-Sep-2023  | 56.74                        | 43.26      | 0.00               | 100.00    |
| 31-Dec-2023  | 56.74                        | 43.26      | 0.00               | 100.00    |
| 31-Mar-2024  | 56.74                        | 43.26      | 0.00               | 100.00    |
| 30-Jun-2024  | 56.38                        | 43.62      | 0.00               | 100.00    |
| 30-Sep-2024  | 55.66                        | 44.34      | 0.00               | 100.00    |

Promoter holding has slightly decreased over the past year, while public holding has increased correspondingly. This warrants further investigation into the reasons behind this shift.

**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week's high and low prices.  The CM Annual Volatility of 29.8% further confirms this.  Risks include the impact of the cybersecurity incident, the divestment of the Indore facility, and general market fluctuations.  The low market depth adds to the risk profile.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Generally increasing revenue and profit (excluding exceptional items).
* Established presence in the pharmaceutical sector.

**8. Disadvantages and Risks:**

* High volatility.
* Recent cybersecurity incident and its potential long-term impact.
* Divestment of the Indore facility and its effect on future performance.
* Low market depth increases price susceptibility.
* Uncertainty regarding the impact of recent announcements.


**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Hold.** The recent price drop and low market depth create uncertainty.  Waiting for clearer market signals is advisable.

* **Medium-Term (3 to 12 months): Hold.**  The company's fundamentals need further evaluation.  Monitoring the impact of the Indore facility divestment and the cybersecurity incident is crucial.

* **Long-Term (1 year and beyond): Hold with Caution.**  Long-term prospects depend on the company's ability to navigate the current challenges and maintain consistent financial performance.  Further due diligence is recommended.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* **Financial Health (out of 10): 7:**  Generally positive financial trends, but impacted by exceptional items and requires deeper ratio analysis.
* **Market Performance (out of 10): 6:**  Mixed performance with high volatility.
* **Volatility and Risk (out of 10): 5:**  High volatility and low market depth present significant risk.
* **Corporate Actions and Governance (out of 10): 7:**  Consistent dividend payouts, but recent events require further scrutiny.
* **Shareholding Patterns (out of 10): 7:**  Stable promoter holding, but recent decrease warrants further investigation.

**Analysis Score (out of 10): 8**

* **Completeness and Data Utilization (out of 10): 9:**  Most data points were used effectively.
* **Accuracy and Clarity (out of 10): 8:**  Analysis is clear, but some aspects require further investigation.
* **Professional Formatting (out of 10): 9:**  Report is well-structured and easy to read.


**11. Professional Recommendation Summary:**

Based on the available data, ALKEM is currently a **Hold** for all investment horizons.  The high volatility, recent negative events, and limited market depth outweigh the positive aspects of consistent dividend payouts and generally increasing revenue.  Further investigation into the company's financial statements, the impact of recent announcements, and a deeper market depth analysis are crucial before considering a "Buy" recommendation.  Investors should closely monitor the company's performance and news before making any investment decisions.
